Telix Pharmaceuticals Acquires Optimal Tracers
- Telix Pharmaceuticals (TLX) enters an agreement with Northern California PET Imaging Center to acquire radiochemistry specialist Optimal Tracers
- The company believes the acquisition will “bolster” its in-house radiochemistry development capability by adding a highly-skilled team and establishing a US-based lab
- Telix will also own Optimal Tracer’s facility, which has a radiation and pharmaceutical manufacturing licence to support pre-clinical and clinical research
- Optimal Tracer’s CEO, Ruth Tesar, says she’s looking forward to providing Telix with the radiochemistry knowledge and experience to contribute to its future success
- TLX shares are trading at $6.78 at 2:49 pm AEDT
